Literature DB >> 19944633

Single nucleotide variation in exon 11 of canine BRCA2 in healthy and cancerous mammary tissue.

Wei-Li Hsu1, Yi-Hsin Huang, Tien-Jye Chang, Min-Liang Wong, Shih-Chieh Chang.   

Abstract

Germline mutations in the BRCA2 tumour suppressor gene are significant risk indicators of breast cancer in women, especially for hereditary breast cancer. The BRCA2 protein interacts via the BRC (breast cancer) domain with RAD51, an essential component of the cellular machinery for the maintenance of genome stability and double strand-breaks repair. Exon 11 is the largest exon of the BRCA2 gene and contains the region encoding eight repeats of the BRC domain. Little is known about the roles of BRCA2 exon 11 in canine mammary tumours. In present study, the entire BRCA2 exon 11 was sequenced in canine mammary tumours. Fifteen mammary gland samples were obtained from four normal mammary glands and 11 mammary tumours (10 malignant and one benign tumours). Comparing sequences of normal mammary glands with those in GenBank (AB043895 and Z75664), a single nucleotide polymorphism (SNP) at codon 2414 G>A (resulting in a lysine to an arginine substitution) was identified. When compared with the normal mammary gland, 19 sporadically distributed point mutations were found in mammary tumours, including 68% of missense and 32% of silent mutations. A high frequency of genetic variations in codon 511 A>C or 2414 A>G were identified in 6/11 cases, and two missense mutations (2414 A>G, 2383 A>C) were located at the fourth repeat of the BRC domains. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944633     DOI: 10.1016/j.tvjl.2009.03.022

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  7 in total

1.  Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumours.

Authors:  S O Enginler; I Akış; T S F Toydemir; K Oztabak; D Haktanir; M C Gündüz; I Kırşan; I Fırat
Journal:  Vet Res Commun       Date:  2013-10-13       Impact factor: 2.459

2.  Establishment of a PCR analysis method for canine BRCA2.

Authors:  Yasunaga Yoshikawa; Masami Morimatsu; Kazuhiko Ochiai; Kento Okuda; Takahiro Taoda; Seishiro Chikazawa; Asako Shimamura; Toshinori Omi; Makoto Bonkobara; Koichi Orino; Kiyotaka Watanabe
Journal:  BMC Res Notes       Date:  2012-04-03

3.  Establishment of primary mixed cell cultures from spontaneous canine mammary tumors: Characterization of classic and new cancer-associated molecules.

Authors:  Luciana B Gentile; Marcia K Nagamine; Luiz R Biondi; Daniel S Sanches; Fábio Toyota; Tatiane M Giovani; Isis P de Jesus; Ivone I M da Fonseca; Nicolle Queiroz-Hazarbassanov; Bruno L Diaz; Cristina de O Massoco Salles Gomes; Maria Lucia Z Dagli
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

Review 4.  A monograph proposing the use of canine mammary tumours as a model for the study of hereditary breast cancer susceptibility genes in humans.

Authors:  Katie Goebel; Nancy D Merner
Journal:  Vet Med Sci       Date:  2017-03-21

Review 5.  Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.

Authors:  Pauline Thumser-Henner; Katarzyna J Nytko; Carla Rohrer Bley
Journal:  BMC Vet Res       Date:  2020-01-31       Impact factor: 2.741

6.  Identification of the core motif of the BRCA2 C-terminal RAD51-binding domain by comparing canine and human BRCA2.

Authors:  Yasunaga Yoshikawa; Masami Morimatsu; Kazuhiko Ochiai; Toshina Ishiguro-Oonuma; Ryo Morioka; Kento Okuda; Koichi Orino
Journal:  J Vet Med Sci       Date:  2021-03-16       Impact factor: 1.267

7.  Effects of the missense mutations in canine BRCA2 on BRC repeat 3 functions and comparative analyses between canine and human BRC repeat 3.

Authors:  Yasunaga Yoshikawa; Kazuhiko Ochiai; Masami Morimatsu; Yu Suzuki; Seiichi Wada; Takahiro Taoda; Satomi Iwai; Seishiro Chikazawa; Koichi Orino; Kiyotaka Watanabe
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.